FDA Clears Two Biomarker Assays for Early Alzheimer's Detect

The Elecsys beta-amyloid (1-42) CSF II and Elecsys phospho-tau (181P) CSF assays are for use in adults aged 55 and older who are being evaluated for cognitive difficulties.

Related Keywords

Thomas Schinecker , Roche Elecsys , Drug Administration , Roche Diagnostics , Alzheimers Disease , Lzheimer Disease , Csf , Tau Proteins , Amyloid Beta , Mci , Mild Cognitive Impairment , Biomarker , Iological Marker , Cognitive Impairment , Brain , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Impairment ,